ClinicalTrials.gg
Sign In

Sarcoma, Synovial clinical trials

The registry lists 133 studies for Sarcoma, Synovial across more than 10 countries. 29 are recruiting or about to start. 25 of them are mainly about Sarcoma, Synovial (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.

Get an email when these change. Save the Sarcoma, Synovial studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
61
Recruiting
25
Terminated
18
Status unknown
10
Active, not recruiting
9
Withdrawn
5

Phase

Phase 2
66
Phase 1
58
Phase 3
15
Early Phase 1
2

Where

United States
80
France
20
United Kingdom
19
Germany
16
Belgium
15
Canada
15

Who runs them

European Organisation for Research and Treatment of Cancer - EORTC (14) · National Cancer Institute (NCI) (14) · Epizyme, Inc. (5) · USWM CT, LLC (5) · Fred Hutchinson Cancer Center (4) · M.D. Anderson Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · Takara Bio Inc. (2)

What is being tested here

Drugs under test in Sarcoma, Synovial studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Doxorubicin1510
Pazopanib115
NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301114
Liposomal doxorubicin102
Dacarbazine112
Brenetafusp101
Peposertib101
Zanzalintinib101
Nogapendekin alfa inbakicept101
Selinexor101

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3 open · Alkylating agents 1 open · Immune checkpoint inhibitors 4 · Angiogenesis inhibitors 3

Coming up

2phase 3 studies under way
9studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 9

Who these studies take

Of the 25 Sarcoma, Synovial studies recruiting now, 13 (52%) set no upper age limit and 9 (36%) stop at 75 or younger. 9 (36%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 25
AgeWomenMen
107 (28%)7 (28%)
1824 (96%)24 (96%)
3022 (88%)22 (88%)
4021 (84%)21 (84%)
5020 (80%)20 (80%)
6519 (76%)19 (76%)
7517 (68%)17 (68%)
8514 (56%)14 (56%)

Across all 133 studies, recruiting or not: 25% stop at 75 or younger and 16% at 65; 46% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Sarcoma, Synovial studies take

Of 18 phase 2 interventional studies under Sarcoma, Synovial, half reached primary completion within 45 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 245 mo30–80 · 18 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Results posted1

Stopped1

Studies

Recruiting first, then most recently updated. Showing 50 of 133. Browse all 133 → or search them.